{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:46:31Z","timestamp":1715996791503},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T00:00:00Z","timestamp":1341360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s11910-012-0295-2","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T19:03:13Z","timestamp":1341342193000},"page":"489-491","source":"Crossref","is-referenced-by-count":10,"title":["New Disease-Modifying Therapies and New Challenges for MS"],"prefix":"10.1007","volume":"12","author":[{"given":"Vijayshree","family":"Yadav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Bourdette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,4]]},"reference":[{"key":"295_CR1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"295_CR2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911\u201323.","journal-title":"N Engl J Med"},{"key":"295_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13365-012-0080-7","volume":"18","author":"A Bellizzi","year":"2012","unstructured":"Bellizzi A, Nardis C, Anzivino E, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18:1\u201311.","journal-title":"J Neurovirol"},{"key":"295_CR4","unstructured":"Biogen Idec communication: PML incidence in patients receiving TYSABRI\u00ae (natalizumab); 2012."},{"key":"295_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS Sorensen","year":"2012","unstructured":"Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18:143\u201352.","journal-title":"Mult Scler"},{"key":"295_CR6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295\u2013303.","journal-title":"Ann Neurol"},{"key":"295_CR7","unstructured":"Product information: TYSABRI(R) intravenous injection, natalizumab intravenous injection. Elan Pharmaceuticals, Inc. (per manufacturer), South San Francisco, CA; 2012."},{"key":"295_CR8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0b013e318245d2d0","volume":"78","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012;78:436\u20137.","journal-title":"Neurology"},{"key":"295_CR9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","volume":"70","author":"C Bozic","year":"2011","unstructured":"Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742\u201350.","journal-title":"Ann Neurol"},{"key":"295_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91\u2013101.","journal-title":"Clin Neuropharmacol"},{"key":"295_CR11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387\u2013401.","journal-title":"N Engl J Med"},{"key":"295_CR12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med"},{"key":"295_CR13","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication. Safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod). 2011 12\/20\/2011. Available from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm284240.htm ."},{"key":"295_CR14","unstructured":"European Medicines Agency: European Medicines Agency starts review of Gilenya (fingolimod). Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2012\/01\/news_detail_001425.jsp&mid=WC0b01ac058004d5c1 . Accessed May 2012."},{"key":"295_CR15","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1177\/1352458511410344","volume":"17","author":"PS Espinosa","year":"2011","unstructured":"Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult Scler. 2011;17:1387\u20139.","journal-title":"Mult Scler"},{"key":"295_CR16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","volume":"115","author":"V Brinkmann","year":"2007","unstructured":"Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84\u2013105.","journal-title":"Pharmacol Ther"},{"key":"295_CR17","unstructured":"Product Information: GILENYA(TM) oral capsules, fingolimod oral capsules. Novartis Pharmaceuticals Corporation (Per Manufacturer), East Hanover, NJ, 2012."},{"key":"295_CR18","unstructured":"U.S. Food and Drug Administration. Gilenya (fingolimod): drug safety communication. safety review of a reported death after the first dose. Available at: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm284355.htm . Accessed May 2012."},{"key":"295_CR19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/WNL.0b013e31821043b5","volume":"76","author":"A Uccelli","year":"2011","unstructured":"Uccelli A, Ginocchio F, Mancardi GL, et al. Primary varicella zoster infection associated with fingolimod treatment. Neurology. 2011;76:1023\u20134.","journal-title":"Neurology"},{"key":"295_CR20","unstructured":"Nealon N. Severe multiple sclerosis relapse on fingolimod. 5th Joint Triennial Congress of the European and Americas Committee for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands; 2011."},{"key":"295_CR21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e31824c46ad","volume":"78","author":"F Castrop","year":"2012","unstructured":"Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology. 2012;78:928\u201330.","journal-title":"Neurology"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-012-0295-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0295-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:28:25Z","timestamp":1559435305000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-012-0295-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,4]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1007\/s11910-012-0295-2","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,4]]}}}